Amgen Assist 360/Amgen FIRST STEP

Patient Support Services Guide 2018


Amgen ASSIST 360
888-427-7478
Amgen FIRST STEP
888-657-8371

Amgen Assist 360 provides several support services for insured, uninsured, and underinsured patients who encounter financial hardships and cannot afford the Amgen medications they are prescribed, including Amgen FIRST STEP and the Amgen Safety Net Foundation.

The complete list of cancer drugs from Amgen is provided in the Table.

Because individual copay foundations have their own eligibility criteria and application process, Amgen urges patients to contact each foundation directly for eligibility information.

Amgen Support Programs

Amgen FIRST STEP

Amgen FIRST STEP helps qualified, commercially insured patients cover their deductible, coinsurance, or copay costs.

Under this program, patients who are prescribed an Amgen-covered medication will:

  • Have no out-of-pocket costs for the first dose
  • For subsequent doses, Amgen pays the patient’s combined out-of-pocket cost in excess of $5 per dose
  • Maximum program benefits are drug-specific and range from $1500 to $20,000 per patient per calendar year.

Amgen Safety Net Foundation

The Amgen Safety Net Foundation is a nonprofit assistance program supported by Amgen that provides qualifying uninsured or underinsured patients with Amgen drugs at no cost.

For patients with government insurance, Medicare, or Medicaid, Amgen Assist 360 also helps by providing referrals to independent nonprofit foundations that can help with paying for medications.

Eligibility

Amgen FIRST STEP

To qualify for the Amgen FIRST STEP program, a patient:

  • Must be prescribed an Amgen drug covered by the program
  • Must have private commercial health insurance coverage for the prescribed medication
  • Must not have government insurance (eg, Medicare, Medicaid)
  • Can have any income level
  • Must not be a resident of a state where coupons or copay programs are not valid.

Amgen Safety Net Foundation

To qualify for this program, a patient must:

  • Be a resident of the United States or its territories
  • Satisfy income eligibility requirements
  • Have no or limited drug coverage
  • Not have any other insurance or financial support options.

In certain cases, patients who are underinsured or who have Medicare Part D coverage may qualify to receive support.

Application & Enrollment

Amgen Assist 360

Patients can enroll in the Amgen Assist 360 Patient Support Program by completing sections 1 and 2 of the Amgen Assist 360 enrollment form.

Healthcare provider and patient authorization are both required for enrollment in the Amgen Safety Net Foundation.

Amgen FIRST STEP

Eligible patients must be enrolled in the individual drug-specific program for the Amgen medication they have been prescribed.

Out-of-pocket costs for Amgen FIRST STEP must be associated with medications purchased and administered at a participating clinic or institution; the clinic or institution must be enrolled in the program before its patients can participate.

The healthcare provider submits the necessary materials and informs the patient if he or she qualified for the program. The Amgen FIRST STEP program MasterCard can be used with mail-order and specialty pharmacies.

The program is valid for the enrolled patient’s entire course of treatment and does not require re-enrollment. However, for continued eligibility, the patient’s explanation of benefits must be submitted within 45 days of each swipe of the Amgen FIRST STEP copay coupon. If the explanation of benefits is delayed, contact the Help Desk (888-657-8371) for an extension.

Amgen Safety Net Foundation

To enroll in the Amgen Safety Net Foundation, patients must submit the Patient Application Form and any supporting materials. The patient and the provider are notified on the approval of the application and what costs will be covered.

The Amgen Safety Net Foundation requires reapplication to the program each year. The foundation has 3 models of enrollment.

Prescription enrollment
This model applies to Amgen drugs that require a prescription and delivery of medication in advance of its administration. For the applicable Amgen drug, this model requires the submission of a drug’s prescription form completed by the prescriber or an original prescription to the foundation.

Replacement enrollment
This model applies to replacement drugs for physician-administered medications. In this model, the Amgen drug is first administered to qualifying foundation patients from the physician’s existing commercial stock, and then the replacement for this drug is ordered from the foundation. These drugs must be administered in an outpatient setting to be eligible for replacement.

On Demand enrollment
This model applies to certain physician-administered Amgen drugs that require delivery of the medication in advance of its administration. In this model, an On Demand Product Request Form is completed by the provider after the patient is enrolled in the foundation.

Receiving Amgen Medications

Amgen Safety Net Foundation

The Amgen Safety Net Foundation has 3 ways of providing medications based on the enrollment model. Check online at AmgenSafetyNetFoundation.com for drug-specific information.

Prescription enrollment
The foundation ships prescription drugs directly to the patient for all drugs included in this model, except for Prolia (denosumab), which is shipped directly to the provider.

Replacement enrollment
These drugs are sent directly to the prescriber.

On Demand enrollment
On Demand drugs are shipped directly to the provider in advance of administration.

Table Amgen Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Aranesp (darbepoetin alfa)
Indication
Chemotherapy-induced anemia
Patient support program

Drug
Blincyto (blinatumomab)
Indication
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Drug
Epogen (epoetin alfa)
Indication
Chemotherapy-induced anemia
Patient support program

Drug
Imlygic (talimogene laherparepvec)
Indication
Melanoma with unresectable cutaneous, subcutaneous, or nodal lesions

Drug
Kyprolis (carfilzomib)
Indication
Relapsed or refractory multiple myeloma, in combination with dexamethasone or with lenalidomide and dexamethasone

Drug
Neulasta (pegfilgrastim)
Indication
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs

Drug
Neupogen (filgrastim)
Indication
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs

Drug
Nplate (romiplostim)
Indication
Thrombocytopenia in patients with chronic immune thrombocytopenia

Drug
Prolia (denosumab)
Indication
Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy

Drug
Vectibix (panitumumab)
Indication
Metastatic colorectal cancer with wild-type KRAS

Drug
Xgeva (denosumab)
Indication
Bone metastasis from solid tumors; unresectable giant-cell tumor of the bone; hypercalcemia of malignancy refractory to bisphosphonate therapy